Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

NCT04478266 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1068

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed.

Conditions

Breast Cancer

Interventions

DRUG: Amcenestrant-matching placebo
DRUG: SAR439859
DRUG: Palbociclib
DRUG: Letrozole
DRUG: Goserelin
DRUG: Letrozole-matching placebo

Sponsor

Sanofi